Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity - Report - MDSpire
Advertisement
Paediatric metabolic dysfunction-associated steatotic liver disease (MASLD): a growing health concern in the age of childhood obesity
Clinical Report: Metabolic Dysfunction-Related Steatotic Liver Disease in Children
Overview
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most prevalent chronic liver disease in children, closely linked to rising obesity rates. The condition often remains asymptomatic in early stages.
Background
The increasing prevalence of MASLD among children and adolescents is a significant public health concern, particularly as it parallels the global rise in pediatric obesity. With prevalence rates of 13% in the general pediatric population and 47% among those with obesity, understanding MASLD's pathophysiology is critical. The condition can progress to severe liver complications.
Data Highlights
No specific numerical data provided in the article.
Key Findings
MASLD is the most common chronic liver disease in children and adolescents.
Prevalence estimates are 13% in the general pediatric population and 47% among children with obesity.
The pathophysiology of MASLD is multifactorial, involving insulin resistance, genetic factors, and gut-liver axis dysregulation.
Pharmacotherapy options for MASLD in children remain limited, with ongoing research into potential treatments.
Clinical Implications
Healthcare professionals should be vigilant in screening for MASLD in children, especially those with obesity.
Conclusion
The rising incidence of MASLD in children necessitates increased awareness. Continued research is essential to address existing gaps in understanding and treatment.
